{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:28:57Z","timestamp":1790306937874,"version":"4.1.0"},"reference-count":55,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"DOI":"10.1136\/jnnp-2015-311100","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T22:49:18Z","timestamp":1445554158000},"page":"jnnp-2015-311100","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":44,"title":["Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group"],"prefix":"10.1136","author":[{"given":"C","family":"McGuigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Craner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Guadagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Mazibrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Molyneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O R","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Rog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C A","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,10,22]]},"reference":[{"key":"key-10.1136\/jnnp-2015-311100-1","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2015-311100-2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2015-311100-3","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2015-311100-4","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"\u00a0Lancet"},{"key":"key-10.1136\/jnnp-2015-311100-5","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"key-10.1136\/jnnp-2015-311100-6","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311100-7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/WNL.0b013e318246d6d8","article-title":"Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance","volume":"78","author":"Blair","year":"2012","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311100-8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fneur.2013.00011","article-title":"Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy","volume":"4","author":"Lind\u00e5","year":"2013","journal-title":"Front Neurol"},{"key":"key-10.1136\/jnnp-2015-311100-9","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00415-012-6759-0","article-title":"Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab","volume":"260","author":"Mc Govern","year":"2013","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2015-311100-10","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1212\/WNL.0b013e31826846b4","article-title":"The earlier, the smaller, the better for natalizumab-associated PML: In MRI vigilance veritas?","volume":"79","author":"Phan-Ba","year":"2012","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311100-11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jnnp-2011-300511","article-title":"MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy","volume":"83","author":"Phan-Ba","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2015-311100-12","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acn3.114","article-title":"Outcome and survival of asymptomatic PML in natalizumab-treated MS patients","volume":"1","author":"Dong-Si","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"key-10.1136\/jnnp-2015-311100-13","unstructured":"Biogen. Tysabri 300\u2005mg concentrate for solution for infusion. Summary of medical product characteristics. http:\/\/www.medicines.org.uk\/EMC\/medicine\/18447\/SPC\/TYSABRI+300+mg+concentrate+for+solution+for+infusion\/ (accessed 24 Jun 2015)."},{"key":"key-10.1136\/jnnp-2015-311100-14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/practneurol-2011-000092","article-title":"Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring","volume":"12","author":"Hunt","year":"2012","journal-title":"Pract Neurol"},{"key":"key-10.1136\/jnnp-2015-311100-15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","article-title":"Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab","volume":"18","author":"S\u00f8rensen","year":"2012","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2015-311100-16","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti\u2013JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2015-311100-17","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1177\/1352458513510224","article-title":"The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"19","author":"Wattjes","year":"2013","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2015-311100-18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ene.12304","article-title":"Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial","volume":"21","author":"Bozic","year":"2014","journal-title":"Eur J Neurol"},{"key":"key-10.1136\/jnnp-2015-311100-19","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2015-311100-20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: Implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2015-311100-21","unstructured":"Biogen. Physician Information and Management Guidelines for Multiple Sclerosis Patients on TYSABRI Therapy. Version 14. Maidenhead: Biogen 2015."},{"key":"key-10.1136\/jnnp-2015-311100-22","article-title":"Natalizumab-Related PML Is Possible Even With Recent Negative JCV Antibody Testing. Poster presented at the 67th American Academy of Neurology Annual Meeting April 18\u201325","author":"Brosseau","year":"2015"},{"key":"key-10.1136\/jnnp-2015-311100-23","unstructured":"EMA. (European Medicines Agency). Tysabri: Procedural steps taken and scientific information after authorisation. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation\/human\/000603\/WC500044692.pdf (accessed 24 Jun 2015)."},{"key":"key-10.1136\/jnnp-2015-311100-24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ana.24051","article-title":"Progressive multifocal leukoencephalopathy after natalizumab discontinuation","volume":"75","author":"Fine","year":"2014","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2015-311100-25","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/WNL.0b013e318253d61e","article-title":"Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS","volume":"78","author":"Gheuens","year":"2012","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311100-26","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/1352458513505353","article-title":"JC-virus seroconversion in multiple sclerosis patients receiving natalizumab","volume":"20","author":"Outteryck","year":"2014","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2015-311100-27","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/jnnp-2012-304332","article-title":"Changes to anti-JCV antibody levels in a Swedish national MS cohort","volume":"84","author":"Warnke","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2015-311100-28","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0b013e3182583022","article-title":"Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort","volume":"78","author":"Trampe","year":"2012","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311100-29","article-title":"Anti-JCV antibody status in MS patients: baseline results of STRATIFY-2","author":"Bozic"},{"key":"key-10.1136\/jnnp-2015-311100-30","doi-asserted-by":"crossref","DOI":"10.1177\/1352458515599681","article-title":"Anti-JC virus antibody titres increase over time with natalizumab treatment","author":"Raffel","year":"2015","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2015-311100-31","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1177\/1352458514567728","article-title":"Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy","volume":"21","author":"Vennegoor","year":"2015","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2015-311100-32","article-title":"Anti\u2013JC virus (JCV) Antibody Index Differentiates Risk of Progressive Multifocal Leukoencephalopathy in Natalizumab-treated Multiple Sclerosis Patients with no Prior Immunosuppressant Use: an Updated Analysis Poster presented at the 67th American Academy of Neurology Annual Meeting April 18\u201325","author":"Kuesters"},{"key":"key-10.1136\/jnnp-2015-311100-33","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2015-311100-34","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/jnnp-2013-304897","article-title":"Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients","volume":"84","author":"Dahlhaus","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2015-311100-35","doi-asserted-by":"crossref","DOI":"10.1007\/s13365-015-0316-4","article-title":"Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy","author":"Dong-Si","year":"2015","journal-title":"J Neurovirol"},{"key":"key-10.1136\/jnnp-2015-311100-36","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s00415-012-6426-5","article-title":"Value of MRI as a surrogate marker for PML in natalizumab long-term therapy","volume":"259","author":"Ayzenberg","year":"2012","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2015-311100-37","volume-title":"STRATIFY JCV DxSelectTM: Enzyme-linked immunosorbent assay (ELISA) for the qualitative detection of human antibodies to JC virus","author":"Focus. Diagnostics","year":"2013"},{"key":"key-10.1136\/jnnp-2015-311100-38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/2040622313514790","article-title":"First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks","volume":"5","author":"Nicholas","year":"2014","journal-title":"Ther Adv Chronic Dis"},{"key":"key-10.1136\/jnnp-2015-311100-39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","article-title":"JC virus antibody status underestimates infection rates","volume":"74","author":"Berger","year":"2013","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2015-311100-40","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamaneurol.2014.63","article-title":"JC virus in cd34+ and cd19+ cells in patients with multiple sclerosis treated with natalizumab","volume":"71","author":"Frohman","year":"2014","journal-title":"JAMA Neurol"},{"key":"key-10.1136\/jnnp-2015-311100-41","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa0810316","article-title":"Progressive multifocal leukoencephalopathy after natalizumab monotherapy","volume":"361","author":"Lind\u00e5","year":"2009","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2015-311100-42","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e31820b7644","article-title":"Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS","volume":"76","author":"Vennegoor","year":"2011","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311100-43","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/ana.23676","article-title":"Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"72","author":"Yousry","year":"2012","journal-title":"Ann Neurol"},{"issue":"4","key":"key-10.1136\/jnnp-2015-311100-44","first-page":"27","article-title":"Imaging findings for PML in natalizumab-treated MS patients","volume":"18","author":"Richert","year":"2012","journal-title":"Mult Scler"},{"key":"key-10.1136\/jnnp-2015-311100-45","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/jnnp-2014-308630","article-title":"MRI pattern in asymptomatic natalizumab-associated PML","volume":"86","author":"Wattjes","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2015-311100-46","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1212\/WNL.44.12.2352","article-title":"Isolated motor control dysfunction related to progressive multifocal leukoencephalopathy during AIDS with normal MRI","volume":"44","author":"de Toffol","year":"1994","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311100-47","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1212\/WNL.0000000000000713","article-title":"JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene","volume":"83","author":"Agnihotri","year":"2014","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311100-48","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ana.23973","article-title":"JC virus granule cell neuronopathy and GCN\u2013IRIS under natalizumab treatment","volume":"74","author":"Schippling","year":"2013","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2015-311100-49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00415-014-7530-5","article-title":"Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature","volume":"262","author":"Wijburg","year":"2015","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2015-311100-50","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jns.2014.09.007","article-title":"Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy","volume":"346","author":"Taieb","year":"2014","journal-title":"J Neurol Sci"},{"key":"key-10.1136\/jnnp-2015-311100-51","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.24153","article-title":"Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Warnke","year":"2014","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2015-311100-52","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s00415-014-7336-5","article-title":"Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?","volume":"261","author":"Wattjes","year":"2014","journal-title":"J Neurol"},{"key":"key-10.1136\/jnnp-2015-311100-53","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2012-302478","article-title":"Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies","volume":"83","author":"Mentzer","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2015-311100-54","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1212\/WNL.0b013e31823b9b27","article-title":"Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS","volume":"77","author":"Kuhle","year":"2011","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2015-311100-55","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1212\/WNL.0b013e31822e55e7","article-title":"Immune reconstitution inflammatory syndrome in natalizumab-associated PML","volume":"77","author":"Tan","year":"2011","journal-title":"Neurology"}],"container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2015-311100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T14:00:55Z","timestamp":1601042455000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2015-311100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,22]]},"references-count":55,"alternative-id":["10.1136\/jnnp-2015-311100"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2015-311100","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,22]]}}}